B-Complex: A Nutraceutical SANS Countermeasure

Sponsor
National Aeronautics and Space Administration (NASA) (U.S. Fed)
Overall Status
Not yet recruiting
CT.gov ID
NCT05366933
Collaborator
Mayo Clinic (Other), Texas A&M University (Other)
16
1
75

Study Details

Study Description

Brief Summary

In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupling and nitric oxide synthesis and 2) optimize collagen firmness and elasticity in the sclera and lamina cribrosa, and 3) minimize changes in total retinal thickness during and after flight.

The protocol includes assessments of ocular health and function, along with determinants of vascular endothelial function, advanced glycation end products, and nutritional status and one carbon biochemistry. These additional measures will be critical for the further definition of the causes of optic disc edema in some astronauts after long-duration space flight, and in understanding the effect of the countermeasure. Finally, the supplemented subjects in this study will be compared against total retinal thickness data from previously flown astronauts known to have not taken supplements during their missions.

Condition or Disease Intervention/Treatment Phase
  • Drug: Vitamin B-Complex Supplement
Phase 1

Detailed Description

Fasting (8-h) blood samples (7.5 mL SST and 5 mL EDTA tubes, 12.5 mL total per session) will be collected approximately 180 days and 45 days before flight, on approximate flight day 90, and 30 days before landing, Return to Earth +0-2 days and 30 days after landing.

Blood samples will be analyzed for vitamin status and one-carbon biochemistry, as previously described. One blood sample (collected before flight) will be analyzed for approximately 511 SNPs matching the profile of testing from our ongoing research related to optic disc edema. Serum samples will be analyzed for biochemistry measures evaluating endothelial function, vitamin status, and oxidative damage.

Nutritional status assessment data, including inflight dietary intake and body mass data, completed for routine medical requirements will be requested for data sharing. Inflight medical exercise log data as well as available standard measures data will also be requested for data sharing. Medication use/Med Logs will also be requested for data sharing.

Vascular function VENDYS-II (Endothelix, Inc) will be used to assess reactive hyperaemia through changes in fingertip temperature. The test consists of an automated blood pressure measurement followed by cuff occlusion of the right arm for 2 to 5 min. During this time, the fingertip temperature in the right hand decreases because of the lack of circulation in the fingertip. After the cuff is released, blood flow resumes, causing a temperature rebound in the fingertip in a manner that is proportional to vascular reactivity.

Advanced Glycation End (AGE) Products Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader (Diagnoptics Technologies, Groningen, the Netherlands). The AGE reader illuminates a skin surface of approximately 4 cm2, guarded against surrounding light, with an excitation light source with wavelength between 300 and 429 nm. This method is based on the fluorescent properties of certain AGEs accumulated in dermal tissue.

OCT and OCT-A Optical coherence tomography (OCT) and OCT-angiography (OCT-A) scans will be acquired using the Spectralis OCT2 (Heidelberg Engineering) before, during, and after flight. The scan pattern includes 24 B-scans centered in a radial pattern over the optic nerve head, as well as a 3.5 mm circle scan surrounding the optic nerve head for assessment of retinal nerve fiber layer thickness and choroid thickness. For OCT-A, five consecutive volume scans will be obtained in these regions, each containing 216 A-scans. These images will be registered, and the consecutive B-scans will be used to calculate the decorrelation among the images to provide split-spectrum amplitude decorrelation angiography (SSADA) images. This decorrelation between consecutive B-scan images will be used to highlight locations where there is blood flow. The density of the perfused peripapillary vessels within the various layers of the retina will be calculated to create a flow density map.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
16 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
B-Complex: A Nutraceutical SANS Countermeasure
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2027
Anticipated Study Completion Date :
Sep 30, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Supplemented with B-Complex

Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station

Drug: Vitamin B-Complex Supplement
Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin

Outcome Measures

Primary Outcome Measures

  1. Optic Disc Edema [6 months]

    Measure change in total retinal thickness during and after flight compared to preflight using OCT

Secondary Outcome Measures

  1. Endothelial function [6 months]

    Assess reactive hyperemia through changes in fingertip temperature

  2. Advanced Glycation End Products (AGE) [6 months]

    Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader

  3. Serum folate status [6 months]

    Vitamin status assessed from a fasting blood sample

  4. Red Blood Cell folate status [6 months]

    Vitamin status assessed from a fasting blood sample

  5. Vitamin B6 status [6 months]

    Vitamin status assessed from a fasting blood sample

  6. Vitamin B12 status [6 months]

    Vitamin status assessed from a fasting blood sample

  7. Glucose [6 months]

    Serum glucose from a fasting blood sample

  8. Nitric oxide [6 months]

    Serum nitric oxide from a fasting blood sample

  9. tetrahydrobiopterin [6 months]

    Serum biochemistry from a fasting blood sample

  10. Dihydrobiopterin [6 months]

    Serum biochemistry from a fasting blood sample

  11. Oxidized glutathione [6 months]

    Serum biochemistry from a fasting blood sample

  12. Total antioxidant capacity [6 months]

    Serum biochemistry from a fasting blood sample

  13. Advanced glycation end products [6 months]

    Serum biochemistry from a fasting blood sample

  14. Albumin [6 months]

    Serum biochemistry from a fasting blood sample

  15. Glycated albumin [6 months]

    Serum biochemistry from a fasting blood sample

  16. 3-nitrotyrosine [6 months]

    Serum biochemistry from a fasting blood sample

  17. Formate [6 months]

    Serum biochemistry from a fasting blood sample

  18. MMP-2 [6 months]

    Serum biochemistry from a fasting blood sample

  19. MMP-9 [6 months]

    Serum biochemistry from a fasting blood sample

  20. TIMP-1 [6 months]

    Serum biochemistry from a fasting blood sample

  21. TIMP-2 [6 months]

    Serum biochemistry from a fasting blood sample

  22. Heparan sulfate [6 months]

    Serum biochemistry from a fasting blood sample

  23. Syndecan-1 [6 months]

    Serum biochemistry from a fasting blood sample

  24. Glypican [6 months]

    Serum biochemistry from a fasting blood sample

  25. Hyaluronan [6 months]

    Serum biochemistry from a fasting blood sample

  26. Total lipid peroxides [6 months]

    Serum biochemistry from a fasting blood sample

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

• Must be astronauts selected for 6-12 month missions on the International Space Station

Exclusion Criteria:

• Subjects taking B-vitamin supplements

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • National Aeronautics and Space Administration (NASA)
  • Mayo Clinic
  • Texas A&M University

Investigators

  • Principal Investigator: Sara R Zwart, PhD, UTMB

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Sara R. Zwart, PhD, Deputy Manager for Nutritional Biochemistry, The University of Texas Medical Branch, Galveston
ClinicalTrials.gov Identifier:
NCT05366933
Other Study ID Numbers:
  • NASA IRB STUDY00000448
First Posted:
May 9, 2022
Last Update Posted:
May 9, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 9, 2022